As majorly disruptive cyberattacks continue to make headlines in the healthcare world, hospitals are prioritizing cybersecurity more than ever before. This piece explores reactions from five different health system executives about the recent attack on Ascension — as well as what they’re doing to prevent a similar fate at their own organization and how they want things to change going forward.
While adopting new technology is obviously a big part of healthcare innovation teams’ work, there are plenty of worthwhile initiatives that don’t involve advanced technologies, pointed out Dan Shoenthal, chief innovation officer at MD Anderson Cancer Center.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Researchers at the University of Texas MD Anderson Cancer Center published two studies this week on a new approach that could improve treatment for patients with pancreatic cancer. The preclinical studies showed that combining immunotherapy with a KRAS inhibitor can lead to long-lasting tumor elimination.
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
Texas has the right environment to help ARPA-H achieve its promise of eliminating existing deficiencies in our national biomedical ecosystem, promoting the integration of multiple disciplines and institutions, and fully addressing persistent inequities in America’s health system.
Researchers at the University of Texas MD Anderson Cancer Center published a new study revealing that cancer cells make their own unique form of collagen to help them grown and proliferate. This means drug developers may have a new, highly specific target for oncology therapeutics.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
An appellate court lifted a $4.3 million HIPAA fine imposed on the Texas-based cancer care center two years ago for losing the personal health information of more than 33,000 people.
Founded in 2017, Artidis has raised $15.1 million and hopes to enter the U.S. market for cancer diagnosis by 2022. But the startup first has to convince the FDA that its device works.
The findings may make it possible to identify a subset of patients who experience poorer outcomes or more serious side effects, especially neurotoxicity.
Data from 11 patients in an MD Anderson study of a cell therapy that uses natural killer (NK) cells from donors instead of patients' own T cells showed a high response rate and low toxicity. A multicenter, international Phase II study is planned.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Kyoto University's Tasuku Honjo and MD Anderson's James Allison will share the prize for work that led to immunotherapy drugs like Keytruda and Yervoy.
The company aims to develop therapeutics focused on antibodies found in patients who respond well to cancer immunotherapies and develop treatments for those who do not.
The decision for all intents and purposes draws a clear line in the sand that encryption, despite being an addressable element under the Security Rule, cannot be avoided.
The violations date back to three separate breach reports in 2012 and 2013, which involve the stealing of an unencrypted laptop and the loss of two unencrypted USB thumb drives.
Rebecca Kaul, chief innovation officer at MD Anderson Cancer Center and a keynote speaker at MedCity CONVERGE, discussed why innovation is needed in healthcare — particularly in the oncology space.